A SELECT trial-derived risk equation showed better discrimination for acute coronary syndrome than the Framingham equation (C-index 0.67 vs 0.57) in overweight/obese patients with CVD but no diabetes.
Observational (n=17,604)
Yes
Does semaglutide reduce acute coronary syndrome and stroke in people with overweight or obesity and established cardiovascular disease without diabetes?
Novel risk equations derived from the SELECT trial accurately predict the risk of secondary cardiovascular events in patients with overweight or obesity and established CVD without diabetes, improving upon the Framingham Recurring CHD risk equation.
Absolute Event Rate: 0.67% vs 0.57%
These novel, treatment-specific, trial-derived risk equations are the first to predict the risk of secondary cardiovascular events in people with overweight or obesity and established cardiovascular disease but without diabetes. Incorporating these risk equations into health economic models may improve the accuracy of economic evaluations in this population.
Bøg et al. (Mon,) conducted a observational in Overweight or obesity and established cardiovascular disease without diabetes (n=17,604). SELECT trial-derived risk equation vs. Framingham Recurring CHD Study risk equation was evaluated on Discrimination for acute coronary syndrome (C-index). A SELECT trial-derived risk equation showed better discrimination for acute coronary syndrome than the Framingham equation (C-index 0.67 vs 0.57) in overweight/obese patients with CVD but no diabetes.